Molecular medicine-based IBD treatment strategies—we take it personally
In light of potentially aggressive disease courses of either IBD type—CD or UC—marked by frequent flareups or non-subsiding inflammatory activity, effective immunosuppression is key to preventing progressive tissue destruction and permanent disability. However, over-treating patients with a high pro...
Saved in:
| Published in | Frontiers in gastroenterology (Lausanne, Switzerland) Vol. 2 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Frontiers Media S.A
09.08.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In light of potentially aggressive disease courses of either IBD type—CD or UC—marked by frequent flareups or non-subsiding inflammatory activity, effective immunosuppression is key to preventing progressive tissue destruction and permanent disability. However, over-treating patients with a high probability of an indolent disease course ought to be avoided. To solve this therapeutic dichotomy, there is a pressing need for a reliable classification of patients based on their biosignature to rate their individual prognosis and likelihood of response to a given therapy. This need for pinpoint therapeutic strategies is addressed by the concepts of PreM and the more stringently defined PerM. In this review we summarize the most pivotal study results published so far in the field of individualized IBD care with a special focus on molecular diagnostics and their applicability in the clinical setting. |
|---|---|
| AbstractList | In light of potentially aggressive disease courses of either IBD type—CD or UC—marked by frequent flareups or non-subsiding inflammatory activity, effective immunosuppression is key to preventing progressive tissue destruction and permanent disability. However, over-treating patients with a high probability of an indolent disease course ought to be avoided. To solve this therapeutic dichotomy, there is a pressing need for a reliable classification of patients based on their biosignature to rate their individual prognosis and likelihood of response to a given therapy. This need for pinpoint therapeutic strategies is addressed by the concepts of PreM and the more stringently defined PerM. In this review we summarize the most pivotal study results published so far in the field of individualized IBD care with a special focus on molecular diagnostics and their applicability in the clinical setting. |
| Author | Hentschel, Viktoria Klaus, Jochen |
| Author_xml | – sequence: 1 givenname: Viktoria surname: Hentschel fullname: Hentschel, Viktoria – sequence: 2 givenname: Jochen surname: Klaus fullname: Klaus, Jochen |
| BookMark | eNpNkEtOwzAURS1UJErpBhhlAyn-JvYQyi9SERMYWy_2c5WSJpUdhDpjEayQldAPQozefXdwrnTOyajrOyTkktGZENpchWUa4oxTLmaM84JKfULGXDORM1aY0b98RqYprSilXJfKSD0m1VPfontvIWZr9I1rOsxrSOiz6uY2GyLCsMZuyHYLMOCywfT9-fWB2QBvmDVDtsGY-g7adntBTgO0Cae_d0Je7-9e5o_54vmhml8vcseU0DmU2kMphHRIZe0KrzAYE7xn3inGBUgtYPcYoRR1NGhgpqCah7oM2gUqJqQ6cn0PK7uJzRri1vbQ2EPRx6WFODSuRVtwFFJhwaRRUgRvuHY1NcYhVyyYPYsfWS72KUUMfzxG7d6tPbi1e7f21634AVmtcHE |
| Cites_doi | 10.1038/nm.3462 10.1053/j.gastro.2017.03.049 10.1016/S0140-6736(18)32167-6 10.1016/S0140-6736(22)00467-6 10.1186/s12876-018-0917-5 10.1136/gutjnl-2017-315671 10.1136/gutjnl-2020-321731 10.1038/ng.3755 10.1007/s00535-021-01819-7 10.1016/j.molcel.2018.11.018 10.1371/journal.pone.0052223 10.1111/bcp.14235 10.1186/s13073-022-01112-z 10.1038/s41586-019-1237-9 10.1038/nm.4307 10.1038/s41467-022-33331-8 10.1016/j.conctc.2019.100345 10.21037/tp.2018.12.03 10.1186/s12876-021-01900-8 10.1377/hlthaff.2017.1624 10.1016/j.chom.2017.04.010 10.1053/j.gastro.2021.10.037 10.1136/gutjnl-2019-318483 10.3390/genes12091438 10.1053/j.gastro.2019.09.041 10.1136/gutjnl-2019-318343 10.1093/ibd/izab032 10.3389/fimmu.2021.622934 10.1007/s10620-018-4924-8 10.1038/nrgastro.2013.253 10.1038/nature16460 10.1056/NEJMoa1602773 10.1016/S0140-6736(17)30317-3 10.1016/j.crohns.2011.06.006 10.1053/j.gastro.2006.11.041 10.3390/jcm10225318 10.3390/ijerph16091551 10.1016/j.cgh.2019.08.030 10.1016/j.cgh.2020.03.066 10.5217/ir.2020.00002 10.1001/jama.2019.0709 10.3389/fmed.2016.00024 10.1177/17562848231173331 10.1111/apt.15870 10.1016/S0140-6736(02)08512-4 10.1016/j.isci.2022.103963 10.1093/ecco-jcc/jjw116 10.1111/apt.13083 10.1038/ng.3060 10.1136/gut.52.4.558 10.1016/j.gie.2017.01.012 10.1053/j.gastro.2021.09.077 10.1038/sj.ejhg.5201130 10.1002/eji.202149764 10.1053/j.gastro.2019.07.025 10.1053/j.gastro.2022.01.047 10.1016/j.ebiom.2019.01.027 10.1038/s41587-023-01674-2 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION DOA |
| DOI | 10.3389/fgstr.2023.1226048 |
| DatabaseName | CrossRef Open Access: DOAJ - Directory of Open Access Journals |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2813-1169 |
| ExternalDocumentID | oai_doaj_org_article_62e345e6149543fd928cb099ce251f90 10_3389_fgstr_2023_1226048 |
| GroupedDBID | 9T4 AAYXX AFPKN ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ |
| ID | FETCH-LOGICAL-c1538-a78da7334ce04bc6d5ef99fdd1dc5123a483ad1d93550c0f8a196082fb7f8cf03 |
| IEDL.DBID | DOA |
| ISSN | 2813-1169 |
| IngestDate | Tue Oct 22 15:11:52 EDT 2024 Thu Sep 12 18:42:56 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1538-a78da7334ce04bc6d5ef99fdd1dc5123a483ad1d93550c0f8a196082fb7f8cf03 |
| OpenAccessLink | https://doaj.org/article/62e345e6149543fd928cb099ce251f90 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_62e345e6149543fd928cb099ce251f90 crossref_primary_10_3389_fgstr_2023_1226048 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-8-9 |
| PublicationDateYYYYMMDD | 2023-08-09 |
| PublicationDate_xml | – month: 08 year: 2023 text: 2023-8-9 day: 09 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in gastroenterology (Lausanne, Switzerland) |
| PublicationYear | 2023 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Verstockt (B20) 2016; 3 Walker (B28) 2019; 321 Nishioka (B49) 2021; 56 Mehto (B17) 2019; 73 Verstockt (B32) 2019; 40 Giachino (B15) 2004; 12 van Vollenhoven (B45) 2018; 392 Verstockt (B33) 2021; 27 Mishra (B31) 2022; 14 Verstockt (B39) 2020; 18 Matsuoka (B25) 2020; 18 Gisbert (B8) 2015; 41 Lamb (B11) 2022; 162 Powell (B52) 2020; 69 Sandborn (B47) 2022; 162 Sazonovs (B24) 2020; 158 West (B34) 2017; 23 Bertani (B41) 2020; 86 Ben-Horin (B9) 2022; 162 Lindemans (B51) 2015; 528 Aden (B37) 2019; 157 Schmitt (B30) 2019; 68 Lloyd-Price (B55) 2019; 569 Wang (B18) 2022; 52 Ashton (B12) 2019; 8 Atreya (B36) 2014; 20 Jung (B19) 2012; 7 Lee (B21) 2017; 49 Feagan (B6) 2016; 375 Colombel (B1) 2007; 132 Heliö (B16) 2003; 52 Ananthakrishnan (B42) 2017; 21 Vieujean (B13) 2023; 16 Ginsburg (B10) 2018; 37 Bertani (B35) 2020; 52 Boden (B38) 2018; 63 Ben-Horin (B5) 2014; 11 Rath (B40) 2017; 86 Sudhakar (B57) 2022; 25 Kugathasan (B22) 2017; 389 Yang (B27) 2014; 46 Schmitt (B44) 2021; 12 Porter (B56) 2019; 14 Pavlidis (B53) 2022; 13 Sands (B48) 2017; 153 Wenger (B3) 2012; 6 Huang (B43) 2023 Aschenbrenner (B50) 2021; 70 Stankovic (B58) 2021; 12 Gisbert (B7) 2021; 10 Torres (B4) 2016; 10 Grover (B26) 2021; 21 D'Haens (B46) 2022; 399 Jessen (B29) 2021; 19 Borecki (B14) 2019; 16 Imhann (B54) 2019; 19 Hanauer (B2) 2002; 359 Biasci (B23) 2019; 68 |
| References_xml | – volume: 20 year: 2014 ident: B36 article-title: In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease publication-title: Nat Med doi: 10.1038/nm.3462 contributor: fullname: Atreya – volume: 153 start-page: 77 year: 2017 ident: B48 article-title: Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: A phase 2a study publication-title: Gastroenterology doi: 10.1053/j.gastro.2017.03.049 contributor: fullname: Sands – volume: 392 year: 2018 ident: B45 article-title: Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study publication-title: Lancet (London England). doi: 10.1016/S0140-6736(18)32167-6 contributor: fullname: van Vollenhoven – volume: 399 year: 2022 ident: B46 article-title: Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials publication-title: Lancet (London England). doi: 10.1016/S0140-6736(22)00467-6 contributor: fullname: D'Haens – volume: 19 start-page: 5 year: 2019 ident: B54 article-title: The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1 publication-title: BMC gastroenterology. doi: 10.1186/s12876-018-0917-5 contributor: fullname: Imhann – volume: 68 year: 2019 ident: B30 article-title: Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease publication-title: Gut doi: 10.1136/gutjnl-2017-315671 contributor: fullname: Schmitt – volume: 70 year: 2021 ident: B50 article-title: Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance publication-title: Gut doi: 10.1136/gutjnl-2020-321731 contributor: fullname: Aschenbrenner – volume: 49 year: 2017 ident: B21 article-title: Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease publication-title: Nat Genet doi: 10.1038/ng.3755 contributor: fullname: Lee – volume: 56 year: 2021 ident: B49 article-title: Mucosal IL23A expression predicts the response to Ustekinumab in inflammatory bowel disease publication-title: J gastroenterology. doi: 10.1007/s00535-021-01819-7 contributor: fullname: Nishioka – volume: 73 start-page: 429 year: 2019 ident: B17 article-title: The Crohn's disease risk factor IRGM limits NLRP3 inflammasome activation by impeding its assembly and by mediating its selective autophagy publication-title: Mol Cell doi: 10.1016/j.molcel.2018.11.018 contributor: fullname: Mehto – volume: 7 year: 2012 ident: B19 article-title: Genotype/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms publication-title: PloS One doi: 10.1371/journal.pone.0052223 contributor: fullname: Jung – volume: 86 year: 2020 ident: B41 article-title: Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.14235 contributor: fullname: Bertani – volume: 14 start-page: 110 year: 2022 ident: B31 article-title: Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease publication-title: Genome Med doi: 10.1186/s13073-022-01112-z contributor: fullname: Mishra – volume: 569 year: 2019 ident: B55 article-title: Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases publication-title: Nature doi: 10.1038/s41586-019-1237-9 contributor: fullname: Lloyd-Price – volume: 23 year: 2017 ident: B34 article-title: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease publication-title: Nat Med doi: 10.1038/nm.4307 contributor: fullname: West – volume: 13 start-page: 5820 year: 2022 ident: B53 article-title: Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy publication-title: Nat Commun doi: 10.1038/s41467-022-33331-8 contributor: fullname: Pavlidis – volume: 14 start-page: 100345 year: 2019 ident: B56 article-title: Cohort profile of the PRoteomic Evaluation and Discovery in an IBD cohort of tri-service subjects (PREDICTS) study: rationale, organization, design, and baseline characteristics publication-title: Contemp Clin trials Commun doi: 10.1016/j.conctc.2019.100345 contributor: fullname: Porter – volume: 8 start-page: 56 year: 2019 ident: B12 article-title: Personalising medicine in inflammatory bowel disease-current and future perspectives publication-title: Trans pediatrics. doi: 10.21037/tp.2018.12.03 contributor: fullname: Ashton – volume: 21 start-page: 327 year: 2021 ident: B26 article-title: TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India publication-title: BMC gastroenterology. doi: 10.1186/s12876-021-01900-8 contributor: fullname: Grover – volume: 37 start-page: 694 year: 2018 ident: B10 article-title: Precision medicine: from science to value publication-title: Health affairs (Project Hope). doi: 10.1377/hlthaff.2017.1624 contributor: fullname: Ginsburg – volume: 21 start-page: 603 year: 2017 ident: B42 article-title: Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases publication-title: Cell Host Microbe doi: 10.1016/j.chom.2017.04.010 contributor: fullname: Ananthakrishnan – volume: 162 year: 2022 ident: B9 article-title: Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials publication-title: Gastroenterology doi: 10.1053/j.gastro.2021.10.037 contributor: fullname: Ben-Horin – volume: 69 year: 2020 ident: B52 article-title: Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells publication-title: Gut doi: 10.1136/gutjnl-2019-318483 contributor: fullname: Powell – volume: 12 start-page: 1438 year: 2021 ident: B58 article-title: Machine learning modeling from omics data as prospective tool for improvement of inflammatory bowel disease diagnosis and clinical classifications publication-title: Genes doi: 10.3390/genes12091438 contributor: fullname: Stankovic – volume: 158 year: 2020 ident: B24 article-title: HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2019.09.041 contributor: fullname: Sazonovs – volume: 68 year: 2019 ident: B23 article-title: A blood-based prognostic biomarker in IBD publication-title: Gut doi: 10.1136/gutjnl-2019-318343 contributor: fullname: Biasci – volume: 27 year: 2021 ident: B33 article-title: Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease publication-title: Inflammatory bowel diseases. doi: 10.1093/ibd/izab032 contributor: fullname: Verstockt – volume: 12 year: 2021 ident: B44 article-title: Role of the IL23/IL17 pathway in Crohn's disease publication-title: Front Immunol doi: 10.3389/fimmu.2021.622934 contributor: fullname: Schmitt – volume: 63 year: 2018 ident: B38 article-title: Identification of candidate biomarkers associated with response to vedolizumab in inflammatory bowel disease publication-title: Digestive Dis Sci doi: 10.1007/s10620-018-4924-8 contributor: fullname: Boden – volume: 11 year: 2014 ident: B5 article-title: Tailoring anti-TNF therapy in IBD: drug levels and disease activity publication-title: Nat Rev Gastroenterol hepatology. doi: 10.1038/nrgastro.2013.253 contributor: fullname: Ben-Horin – volume: 528 year: 2015 ident: B51 article-title: Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration publication-title: Nature doi: 10.1038/nature16460 contributor: fullname: Lindemans – volume: 375 year: 2016 ident: B6 article-title: Ustekinumab as induction and maintenance therapy for Crohn's disease publication-title: New Engl J Med doi: 10.1056/NEJMoa1602773 contributor: fullname: Feagan – volume: 389 year: 2017 ident: B22 article-title: Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study publication-title: Lancet (London England). doi: 10.1016/S0140-6736(17)30317-3 contributor: fullname: Kugathasan – volume: 6 year: 2012 ident: B3 article-title: Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease publication-title: J Crohn's colitis. doi: 10.1016/j.crohns.2011.06.006 contributor: fullname: Wenger – volume: 132 start-page: 52 year: 2007 ident: B1 article-title: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial publication-title: Gastroenterology doi: 10.1053/j.gastro.2006.11.041 contributor: fullname: Colombel – volume: 10 start-page: 5318 year: 2021 ident: B7 article-title: Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action) publication-title: J Clin Med doi: 10.3390/jcm10225318 contributor: fullname: Gisbert – volume: 16 start-page: 1551 year: 2019 ident: B14 article-title: Relationship between the IL23R SNPs and Crohn's disease susceptibility and phenotype in the polish and bosnian populations: A case-control study publication-title: Int J Environ Res Public Health doi: 10.3390/ijerph16091551 contributor: fullname: Borecki – volume: 18 start-page: 1142 year: 2020 ident: B39 article-title: Expression levels of 4 genes in colon tissue might be used to predict which patients will enter endoscopic remission after vedolizumab therapy for inflammatory bowel diseases publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2019.08.030 contributor: fullname: Verstockt – volume: 19 start-page: 721 year: 2021 ident: B29 article-title: Level of tumor necrosis factor production by stimulated blood mononuclear cells can be used to predict response of patients with inflammatory bowel diseases to infliximab publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2020.03.066 contributor: fullname: Jessen – volume: 18 year: 2020 ident: B25 article-title: NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease publication-title: Intestinal Res doi: 10.5217/ir.2020.00002 contributor: fullname: Matsuoka – volume: 321 year: 2019 ident: B28 article-title: Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease publication-title: Jama doi: 10.1001/jama.2019.0709 contributor: fullname: Walker – volume: 3 year: 2016 ident: B20 article-title: Genetic influences on the development of fibrosis in Crohn's disease publication-title: Front Med doi: 10.3389/fmed.2016.00024 contributor: fullname: Verstockt – volume: 16 start-page: 17562848231173331 year: 2023 ident: B13 article-title: Precision medicine and drug optimization in adult inflammatory bowel disease patients publication-title: Ther Adv gastroenterology. doi: 10.1177/17562848231173331 contributor: fullname: Vieujean – volume: 52 year: 2020 ident: B35 article-title: Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab publication-title: Alimentary Pharmacol Ther doi: 10.1111/apt.15870 contributor: fullname: Bertani – volume: 359 year: 2002 ident: B2 article-title: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial publication-title: Lancet (London England). doi: 10.1016/S0140-6736(02)08512-4 contributor: fullname: Hanauer – volume: 25 start-page: 103963 year: 2022 ident: B57 article-title: Integrated analysis of microbe-host interactions in Crohn's disease reveals potential mechanisms of microbial proteins on host gene expression publication-title: iScience doi: 10.1016/j.isci.2022.103963 contributor: fullname: Sudhakar – volume: 10 year: 2016 ident: B4 article-title: Predicting outcomes to optimize disease management in inflammatory bowel diseases publication-title: J Crohn's colitis. doi: 10.1093/ecco-jcc/jjw116 contributor: fullname: Torres – volume: 41 year: 2015 ident: B8 article-title: Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed publication-title: Alimentary Pharmacol Ther doi: 10.1111/apt.13083 contributor: fullname: Gisbert – volume: 46 year: 2014 ident: B27 article-title: A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia publication-title: Nat Genet doi: 10.1038/ng.3060 contributor: fullname: Yang – volume: 52 year: 2003 ident: B16 article-title: CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease publication-title: Gut doi: 10.1136/gut.52.4.558 contributor: fullname: Heliö – volume: 86 year: 2017 ident: B40 article-title: Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn's disease publication-title: Gastrointestinal endoscopy. doi: 10.1016/j.gie.2017.01.012 contributor: fullname: Rath – volume: 162 year: 2022 ident: B11 article-title: The future of precision medicine to predict outcomes and control tissue remodeling in inflammatory bowel disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2021.09.077 contributor: fullname: Lamb – volume: 12 year: 2004 ident: B15 article-title: Analysis of the CARD15 variants R702W, G908R and L1007fs in Italian IBD patients publication-title: Eur J Hum Genet EJHG. doi: 10.1038/sj.ejhg.5201130 contributor: fullname: Giachino – volume: 52 year: 2022 ident: B18 article-title: ATG16L2 inhibits NLRP3 inflammasome activation through promoting ATG5-12-16L1 complex assembly and autophagy publication-title: Eur J Immunol doi: 10.1002/eji.202149764 contributor: fullname: Wang – volume: 157 start-page: 1279 year: 2019 ident: B37 article-title: Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases publication-title: Gastroenterology doi: 10.1053/j.gastro.2019.07.025 contributor: fullname: Aden – volume: 162 start-page: 1650 year: 2022 ident: B47 article-title: Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study publication-title: Gastroenterology doi: 10.1053/j.gastro.2022.01.047 contributor: fullname: Sandborn – volume: 40 year: 2019 ident: B32 article-title: Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease publication-title: EBioMedicine doi: 10.1016/j.ebiom.2019.01.027 contributor: fullname: Verstockt – year: 2023 ident: B43 article-title: High-throughput microbial culturomics using automation and machine learning publication-title: Nat Biotechnol doi: 10.1038/s41587-023-01674-2 contributor: fullname: Huang |
| SSID | ssj0002875948 |
| Score | 2.2754738 |
| Snippet | In light of potentially aggressive disease courses of either IBD type—CD or UC—marked by frequent flareups or non-subsiding inflammatory activity, effective... |
| SourceID | doaj crossref |
| SourceType | Open Website Aggregation Database |
| SubjectTerms | biomarker Crohn’s disease personalized medicine (PM) prediction of response to therapy ulcerative colitis |
| Title | Molecular medicine-based IBD treatment strategies—we take it personally |
| URI | https://doaj.org/article/62e345e6149543fd928cb099ce251f90 |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV27TsMwFLVQJxYEAkR5yQMbCnVsx45HClQtUpmo1M3yE_FQqWgQYuMj-EK-BNtJqmwsjImiyDqOc85Jrs8F4AzraI61zrD3waAwRzPhiQnLXTGCiUE87eKf3rHxjN7Oi3mn1VesCavjgWvgBgw7QgvHopKnxFuBS6ODrDEuMLMXtVtHomOmntInIx5zSOpdMsGFiYF_WFUx_xOTizxIDhQb_nSYqBPYn5hltA22GkkIL-uh7IANt9gFk2nbtxa2v7-zyDgWTobXcF0eDldVm_Xw8_X94WClnh18rOCyEdkvn3tgNrq5vxpnTduDzKTXj-KlVZwQahyi2jBbOC-Etza3JtAzUbQkKhzEZHRkkC9VWEWByb3mvjQekX3QW7wu3AGAzOHcUWODEWVUc11yhQ23XHhlHc19H5y3EMhlnW4hgyuIgMkEmIyAyQawPhhGlNZXxmTqdCLMl2zmS_41X4f_cZMjsBkHlgrxxDHoVW_v7iSIg0qfpufgF9rSt2w |
| link.rule.ids | 315,783,787,867,2109,27936,27937 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+medicine-based+IBD+treatment+strategies%E2%80%94we+take+it+personally&rft.jtitle=Frontiers+in+gastroenterology+%28Lausanne%2C+Switzerland%29&rft.au=Hentschel%2C+Viktoria&rft.au=Klaus%2C+Jochen&rft.date=2023-08-09&rft.issn=2813-1169&rft.eissn=2813-1169&rft.volume=2&rft_id=info:doi/10.3389%2Ffgstr.2023.1226048&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fgstr_2023_1226048 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2813-1169&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2813-1169&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2813-1169&client=summon |